BioLife Solutions Inc. (BLFS) is a publicly traded Healthcare sector company. As of May 21, 2026, BLFS trades at $24.00 with a market cap of $1.09B and a P/E ratio of -401.10. BLFS moved +4.43% today. Year to date, BLFS is -5.18%; over the trailing twelve months it is +5.22%. Its 52-week range spans $17.86 to $29.62. Analyst consensus is strong buy with an average price target of $33.00. Rallies surfaces BLFS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
BioLife Solutions' Q1 Revenue Rises 25% to $27.5M with $6.2M EBITDA: BioLife Solutions posted Q1 revenue of $27.5 million, up 25% year-over-year, with non-GAAP adjusted EBITDA of $6.2 million (22% of revenue) and GAAP net income of $1.2 million. The company holds a >70% market share in biopreservation media across 250 clinical trials and reaffirmed 2026 revenue guidance of $112.5M-$115M.
| Metric | Value |
|---|---|
| Price | $24.00 |
| Market Cap | $1.09B |
| P/E Ratio | -401.10 |
| EPS | $-0.06 |
| Dividend Yield | 0.00% |
| 52-Week High | $29.62 |
| 52-Week Low | $17.86 |
| Volume | 947 |
| Avg Volume | 0 |
| Revenue (TTM) | $99.77M |
| Net Income | $-2.96M |
| Gross Margin | 64.96% |
6 analysts cover BLFS: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $33.00.